Latest close
$1,182.62
As of Oct 12, 2026
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Polen Capital Management | 6.89% | 666,912 | TRIMMED (-27.1%) |
| Jensen Investment Management | 4.47% | 153,735 | TRIMMED (-33.4%) |
| Mairs & Power Funds | 3.54% | 322,129 | TRIMMED (-1.3%) |
| Torray Funds | 0.06% | 398 | HELD |
| Matrix Asset Advisors | 0.03% | 311 | HELD |
| Dodge & Cox Funds | 0.03% | 41,258 | TRIMMED (-1.8%) |
| Oakmark Funds | <0.01% | 431 | TRIMMED (-4.2%) |
Source: SEC Form 13F filings for the quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. 13F filings cover long positions only and arrive up to 45 days after quarter-end. Fund counts here aggregate every share class mapped to this ticker; research headlines cite filer counts as they stood at publication, so a count here can differ from a headline by a holder (see Methodology, "How holder counts are counted").
| Institutions holding | 4,631 of 8,857 filers |
| Long-only filers among them | 4,618 |
| Change vs 2026 Q1 | +310 net · 2,209 entered · 1,899 exited |
| Shares reported, all filers | 781,924,285 |
| Reported value, all filers | $942.1B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Revenue · FY2025 | $65.2B |
| Net income · FY2025 | $20.6B |
| Total assets · FY2025 | $112.5B |
| Shares outstanding | 941,357,065 |
| Market cap (at latest close) | $1,113.3B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 7, 2026. Shares outstanding as reported Aug 3, 2026.
| Shares short · Sep 15, 2026 | 7,519,918 |
| Share of shares outstanding | 0.80% |
| Days to cover | 3.41 |
Shares short at recent settlements — Jun 30, 2026: 9.4M · Jul 15, 2026: 10.3M · Jul 31, 2026: 9.1M · Aug 14, 2026: 6.6M · Aug 31, 2026: 7.9M · Sep 15, 2026: 7.5M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Aug 3, 2026.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 3 sales by 3 insiders ($16.0M).
Source: SEC Form 4 filings, as of Oct 13, 2026. Open-market transactions only.
2 members of Congress reported buying (3 purchases vs 3 sales). Bought by Democrats and Republicans. Latest buy: Jun 10, 2026.
Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Oct 3, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.
Politicians
· Bought by Members — Last 6 months: bought by a member of the U.S. Congress
· Bought by Both Parties — Last 6 months: bought by both Democratic and Republican members
Financial Screens
· Buffett — Companies with high ROE sustained for more than a decade
· Growth — Revenue up every year for 5 straight years
· Graham — Sound finances and a long run of profits
· Dividend Growth — Dividends raised for more than 10 years
· O'Neil CAN SLIM — Explosive earnings growth leaders
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
· Top Relative Strength — Top 20% of the universe by 6-month return
Key figures
· Buffett — Latest ROE: 74.2% · Years ROE ≥15% (of 10): 9 · 10-yr avg ROE: 72.0% · Latest net income: $10.6B
· Growth — Latest revenue: $65.2B · 5-yr revenue CAGR: 21.6% · Straight growth years: 8
· Graham — Current ratio: 1.58 · Straight profitable years: 8 · Debt ratio: — · Latest net income: $20.6B
· Dividend Growth — Dividend per share: 6.23 · Dividend yield: 0.5% · Straight dividend years: 14 · 10-yr dividend growth: 203.9%
· O'Neil CAN SLIM — 3-yr EPS growth: 49.3% · ROE: 74.2% · Latest revenue growth: 44.7%
· Bought by Members — Members buying: 2 · Buy txns: 3 · Sell txns: 3 · Latest buy: Jun 10, 2026
· Bought by Both Parties — Members buying: 2 · Buy txns: 3 · Sell txns: 3 · Latest buy: Jun 10, 2026
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Super-investor 13F BEST — appeared in 1 of the last 20 quarterly lists; latest 2025 Q2, ranked #35 of 50.
· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2025 Q3, ranked #5 of 50.
· Politician BEST — appeared in 12 of the last 20 quarterly lists; latest 2026 Q2, ranked #15 of 50.
| 13F signal (2021 Q3 – 2026 Q1) | Events | Win rate | Avg return | SPY | Excess |
|---|---|---|---|---|---|
| Heavy accumulation — 3+ tracked funds increased together | 7 | 57.1% | +7.9% | +3.6% | +4.3% |
| Heavy exit — 3+ tracked funds sold out together | 1 | 100.0% | +1.6% | +2.9% | -1.3% |
Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.
Also held by the tracked funds that hold LLY: Alphabet Inc. (GOOGL) · MICROSOFT CORP (MSFT) · AMAZON COM INC (AMZN) · Apple Inc. (AAPL) · NVIDIA CORP (NVDA) · Broadcom Inc. (AVGO) · Alphabet Inc. (GOOG) · Meta Platforms, Inc. (META) · VISA INC. (V) · Accenture plc (ACN).
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.